cox2  (Santa Cruz Biotechnology)

Journal: Annals of Medicine

Article Title: MNS induces antiviral protection and suppresses inflammation

doi: 10.1080/07853890.2026.2662146

Figure Lengend Snippet: MNS suppressed virus-induced and LPS-induced inflammatory responses. (A–C) IL1B mRNA (qPCR) and protein levels (ELISA) in RAW 264.7 cells (A), BMDMs (B), and THP1 cells (C) following treatment with DMSO or MNS and infection with indicated viruses. (D-G) Il1b expression (qPCR) and protein levels (ELISA) in liver tissues from C57BL/6J mice under viral challenge and MNS treatment. (H) MNS markedly downregulated the expression of Il1b , Il6 , Tnfα , Ptgs2 , Nos2 mRNA in RAW264.7 cells. (I) MNS significantly reduced the expression of COX2, iNOS, p-IκBα, p-P65 at the protein level. (J) MNS treatment led to a significant reduction in mortality among LPS-challenged mice (n = 13). (K) The expression level of Il1b in heart, spleen, lung, kidney, and liver was quantified by RT-qPCR. Values are presented as mean ± SEM. Significance was indicated as follows: N.S., p > 0.05; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

Article Snippet: Rabbit anti-COX2 antibody was obtained from Wanleibio.

Techniques: Virus, Enzyme-linked Immunosorbent Assay, Infection, Expressing, Quantitative RT-PCR

Journal: Biomedical Reports

Article Title: Peroxiredoxin 4 suppresses ferroptosis in esophageal squamous cell carcinoma by activating the phosphoinositide 3-kinase  signaling pathway

doi: 10.3892/br.2026.2133

Figure Lengend Snippet: PRDX4 is an important regulator of ferroptosis in ESCC cells. (A) Determination of MDA, LPO and GSH contents in KYSE270 cells after transfection with PRDX4 siRNA. (B) Western blot analysis of the protein levels of GPX4, SLC7A11 and PTGS2 in KYSE270 cells transfected with PRDX4 siRNA. (C) The relative protein levels of GPX4, SLC7A11 and PTGS2 in KYSE270 cells transfected with PRDX4 siRNA. (D) Determination of MDA, LPO and GSH contents in KYSE30 cells after transfection with pcDNA3.1-PRDX4. (E) Western blot analysis of the protein levels of GPX4, SLC7A11 and PTGS2 in KYSE30 cells transfected with pcDNA3.1-PRDX4. (F) The relative protein levels of GPX4, SLC7A11 and PTGS2 in KYSE30 cells transfected with pcDNA3.1-PRDX4. (G) Detection of the levels of MDA, LPO and GSH in the control group, PRDX4 siRNA group and PRDX4 siRNA plus Fer-1 group in KYSE270 cells. (H) Western blot analysis of the protein expression levels of GPX4, SLC7A11 and PTGS2 in the control group, PRDX4 siRNA group and PRDX4 siRNA plus Fer-1 group in KYSE270 cells. (I) The relative protein levels of GPX4, SLC7A11 and PTGS2 in the control group, PRDX4 siRNA group and PRDX4 siRNA plus Fer-1 group in KYSE270 cells. (J) Detection of the levels of MDA, LPO and GSH in the pcDNA3.1 group, pcDNA3.1-PRDX4 group and pcDNA3.1-PRDX4 plus erastin group in KYSE30 cells. (K) Western blot analysis of the protein expression levels of GPX4, SLC7A11 and PTGS2 in the pcDNA3.1 group, pcDNA3.1-PRDX4 group and pcDNA3.1-PRDX4 plus erastin group in KYSE30 cells. (L) The relative protein levels of GPX4, SLC7A11 and PTGS2 in the pcDNA3.1 group, pcDNA3.1-PRDX4 group and pcDNA3.1-PRDX4 plus erastin group in KYSE30 cells. ** P<0.01, *** P<0.001 and **** P<0.0001, indicate statistical significance. PRDX4, peroxiredoxin 4; ESCC, esophageal squamous cell carcinoma; siRNA, small interfering RNA; MDA, malondialdehyde; LPO, lipid peroxidation; GSH, glutathione; GPX4, glutathione peroxidase 4; SLC7A11, solute carrier family 7 member 11; PTGS2, prostaglandin-endoperoxide synthase 2; Fer-1, ferrostatin-1; ns, not significant.

Article Snippet: The primary antibodies were as follows: Anti-PRDX4 (1:2,000 dilution; cat. no. 10703-1-AP), anti-E-cadherin (1:20,000 dilution; cat. no. 20874-1-AP), anti-N-cadherin (1:2,000 dilution; cat. no. 22018-1-AP), anti-Vimentin (1:20,000 dilution; cat. no. 10366-1-AP), and anti-GPX4 (1:1,000 dilution; cat. no. 30388-1-AP; all from Proteintech Group, Inc.), anti-solute carrier family 7 member 11 (SLC7A11; 1:1,000 dilution; cat. no. DF12509; Affinity Biosciences, Ltd.), anti-prostaglandin-endoperoxide synthase 2 (PTGS2; 1:1,000 dilution; cat. no. 27308-1-AP; Proteintech Group, Inc.), anti-p-PI3K (1:1,000 dilution; cat. no. AP0427; ABclonal Biotech Co., Ltd.), anti-PI3K (1:1,000 dilution; cat. no. A19742; ABclonal Biotech Co., Ltd.), anti-p-AKT (1:2,000 dilution; cat. no. 28731-1-AP; Proteintech Group, Inc.), anti-AKT (1:2,000 dilution; cat. no. 10176-2-AP; Proteintech Group, Inc.) and anti-β-actin (1:2,000 dilution; cat. no. 20536-1-AP; Proteintech Group, Inc.).

Techniques: Transfection, Western Blot, Control, Expressing, Small Interfering RNA